ZOLADEX
ASTRAZENECA
Identification
- Active ingredient (INN)
- GOSERELINE ACETATE EXPRIME EN GOSERELINE
- Internal code
- 09 J 138
- Country of Origin
- France
- Pharmaceutical form
- SC Implant in Pre-filled Syringe
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/01 seringue avec système de securite
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Indications
- Treatment of metastasis prostate cancer.
- Adjunctive treatment for external radiation therapy in locally advanced prostate cancer (T3 -T4 stage of the TNM classification or stage C of the AUA classification).
Mechanism of Action
Pharmacotherapeutic group
HORMONE ANALOGUE ENTRAINING GONadotrophin LIBERATION, ATC code: L02AE03 Goséréline is a natural HL-HR analogue agonist synthetic decapeptide.
Chronic administration of goséréline acetate results in a significant reduction in pituitary HL levels and plasma testosterone at the level usually observed in men who have undergone surgical castration, which is maintained throughout the duration of treatment.
In humans, upon initiation of treatment with goséréline acetate, initial stimulation of LH secretion results in a transient increase in plasma testosterone.
However, approximately three weeks after the first injection, the plasma concentration of testosterone returns to castration and remains at that level with treatment administered every three months.
If, as an exceptional measure, the injection renewal did not occur at three months, studies have shown that testosterone concentrations were kept below the castration threshold for up to 85% of patients.
Adverse Effects
The following frequency categories are based on all the adverse reactions of the patient's laboratory and the patient's laboratory.